Telehealth is moving ahead of the evidence
Some telehealth companies are already offering GLP-1 drugs to people with substance use disorders, even though the FDA hasn’t decided whether these medicines should be used to treat addiction. The companies named in the source—Quel, Livelyhood and Choose Your Horizon—are marketing prescriptions for that purpose now. Their activity puts a practical question ahead of the formal one: what should happen when early promise attracts patients and providers before evidence and review have caught up?
GLP-1 drugs are best known for their use in metabolic care. Interest in their possible relationship to substance use has grown because researchers and clinicians are examining whether these medicines might affect appetite, reward, or patterns of consumption. That possibility is not the same as proof that they treat addiction. A biological explanation can make a research question plausible; it can’t establish whether a medicine helps patients, which patients might benefit, or what risks follow from using it for a new purpose.
That distinction matters in telehealth, where a service can connect a patient with a prescriber and arrange access to medication without the familiar infrastructure of an in-person clinic. The convenience can lower practical barriers to seeking care. It can also make a new treatment offer feel more settled than the underlying evidence warrants, especially when the marketing reaches people looking for help with a difficult, often recurring condition.
What “off-label” does—and doesn’t—mean
The source describes these prescriptions as off-label: the drugs are being prescribed for a purpose that hasn’t received an FDA decision. That status shouldn’t be mistaken for a finding that the treatment works for addiction. Nor does the lack of a decision, by itself, answer whether an individual clinician may prescribe a medicine in a particular case. The central point is narrower: companies are presenting a use for which formal review remains unresolved, while the evidence is still developing.
For patients, those distinctions can be hard to see from a brief online pitch. A company’s willingness to offer a prescription may sound like an endorsement of the treatment’s effectiveness. But prescribing, marketing, and establishing that a treatment works are different activities. Evidence has to address outcomes that matter to patients, not just a plausible mechanism or reports that have prompted further interest.
Substance use disorders also don’t describe one uniform clinical situation. A treatment’s effects could differ across substances, patterns of use, health histories, and concurrent care. The source says the drugs show particular promise for alcohol use disorder, but it doesn’t establish that benefit for every patient, or show that findings related to alcohol apply to other substance use disorders. That gap between a promising signal and a clear treatment role is where careful clinical judgment becomes especially important.
Compounded versions add another layer
Some providers are also offering compounded versions of these drugs, which the source says haven’t been approved by regulators. Compounding refers generally to preparing a medication for an individual patient; it doesn’t turn that product into a regulator-approved version of a drug for a new use. The distinction matters because patients may hear the same drug category discussed and assume every product offered has the same review status.
Compounded products raise questions beyond whether GLP-1 medicines might help with addiction. Patients and prescribers also need to understand what product is being supplied, how it was prepared, and what oversight applies. The source doesn’t provide details about the specific products or providers’ practices, so it can’t support conclusions about their quality or safety. It does show that the treatment question and the product question are arriving together.
That combination deserves scrutiny. When a medicine is being offered for an unsettled use in a product form that hasn’t been approved by regulators, a patient may have to assess multiple uncertainties at once. A clear explanation of what’s known, what remains unknown, and why a clinician recommends a particular approach becomes more than a formality. It’s part of informed care.
Promise needs to be tested in the open
Here’s the thing: early interest can be useful without being conclusive. Clinicians and researchers often investigate new uses for existing medicines because established drugs can raise promising questions worth studying. But a promising possibility is a starting point for evaluation, not a substitute for it. Researchers need to determine whether any observed benefit is reliable, how large it is, who experiences it, and how it compares with other forms of care.
The distinction is especially relevant for addiction treatment, where the consequences of an ineffective approach can include delayed care and continued harm. That doesn’t mean these drugs can’t help. It means patients and providers need a careful account of the limits, rather than an implication that a novel prescription has already settled the question.
(And this is the part most people overlook.) The way a treatment is delivered can shape how credible it feels. An online intake, a clinician consultation, and a prescription can look like a complete pathway, yet the existence of that pathway doesn’t answer whether the medicine has been shown to treat the condition. Access is a feature of the service. Evidence is a separate matter.
What the next phase will mean
The FDA’s eventual view remains an open question, according to the source. Until there’s a decision, the practical picture is likely to remain uneven: some companies are offering off-label prescriptions, some providers are offering compounded versions, and the evidence has not yet resolved the treatment’s role. That uncertainty is meaningful for patients weighing care options and for clinicians deciding how to discuss an emerging use.
If you're working in this space, the useful standard is plain communication. Patients should be able to distinguish a research signal from an established treatment claim, and a compounded product from one that has been approved by regulators. They should also understand that the source identifies alcohol use disorder as an area of particular promise without establishing the same outlook across all substance use disorders.
This is more significant than it looks, but not because the treatment question has already been answered. It shows how quickly commercial availability can move when a medical hypothesis attracts interest. The test now is whether evidence and review can give patients a clearer basis for decisions. For the moment, the promise is real enough to examine. The certainty isn’t.